Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia

Diabetes and Vascular Disease Research

Volumn 10, Issue 3, 2013, Pages 256-262

  Goldberg, Ronald B ^a   Rosenson, Robert S ^b   Hernandez Triana, Eric ^c   Misir, Soamnauth ^d   Jones, Michael R ^d  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSIDAD DEL ROSARIO   (Colombia)

^d DAIICHI SANKYO INC   (United States)

Author keywords

Apolipoprotein; colesevelam; lipoprotein particles; low density lipoprotein; prediabetes; primary hyperlipidaemia

Indexed keywords

COLESEVELAM; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLELITHIASIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CYSTOCELE; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INTENTION TO TREAT ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PARTICLE SIZE; PATIENT PREFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ALLYLAMINE; CHOLESTEROL, LDL; CONSTIPATION; DIARRHEA; DOUBLE-BLIND METHOD; DYSPEPSIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INTENTION TO TREAT ANALYSIS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, VLDL; MALE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PARTICLE SIZE; PREDIABETIC STATE; TRIGLYCERIDES;

EID: 84876038812     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164112461657     Document Type: Article

References (32)

1. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010 ; 55: 1310-1317
2. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 ; 52: 453-462 (Pubitemid 36173203)
3. Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 ; 31: 811-822
4. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-2497
5. Blake GJ, Otvos JD, Rifai N, et al. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002 ; 106: 1930-1937 (Pubitemid 35176297)
6. Kuller L, Arnold A, Tracy R, et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. Arterioscler Thromb Vasc Biol. 2002 ; 22: 1175-1180 (Pubitemid 34764870)
7. El Harchaoui K, Van Der, Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007 ; 49: 547-553 (Pubitemid 46177441)
8. Mora S, Szklo M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2007 ; 192: 211-217 (Pubitemid 46602300)
9. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation. 2006 ; 113: 1556-1563 (Pubitemid 43739414)
10. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol. 2002 ; 90: 89-94 (Pubitemid 34775113)
11. Mora S, Otvos JD, Rifai N, et al. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009 ; 119: 931-939
12. Mora S, Otvos JD, Rosenson RS, et al. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010 ; 59: 1153-1160
13. Paynter NP, Sesso HD, Conen D, et al. Lipoprotein subclass abnormalities and incident hypertension in initially healthy women. Clin Chem. 2011 ; 57: 1178-1187
14. Rosenson RS, Davidson MH, Pourfarzib R. Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010 ; 213: 1-7
15. Rizzo M, Pernice V, Frasheri A, et al. Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clin Endocrinol (Oxf). 2009 ; 70: 870-875
16. Sacks FM, Campos H. Clinical review 163: cardiovascular endocrinology: low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003 ; 88: 4525-4532 (Pubitemid 37357487)
17. El Harchaoui K, Arsenault BJ, Franssen R, et al. High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med. 2009 ; 150: 84-93
18. Mackey RH, Greenland P, Goff DC, et al. High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2012 ; 60: 508-516
19. US prescribing information. Parsippany, NJ: Daiichi Sankyo, Inc ; 2012 :
20. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999 ; 159: 1893-1900 (Pubitemid 29424709)
21. Rosenson RS. Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia. Atherosclerosis. 2006 ; 185: 327-330
22. Rosenson RS, Abby SL, Jones MR. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. Atherosclerosis. 2009 ; 204: 342-344
23. Handelsman Y, Goldberg RB, Garvey WT, et al. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 ; 16: 617-628
24. Rosenstock J, Fonseca VA, Garvey WT, et al. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 ; 16: 629-640
25. Jones MR, Mudaliar S, Hernandez-Triana E, et al. Rationale and design of a clinical trial to evaluate metformin and colesevelam HCl as first-line therapy in type 2 diabetes and colesevelam HCl in prediabetes. Curr Med Res Opin. 2009 ; 25: 2239-2249
26. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. http://www.who.int/diabetes/publications/ Definition%20and%20diagnosis%20of%20diabetes-new.pdf (2006, accessed 6 March 2012).
27. Hainline A, Karon J, Lippel K Manual of laboratory operations: lipid and lipoprotein analysis. 2 nd ed. (HEW Pub. No. (NIH) 75-628 (rev.), US Government Printing Office Publication No. 1982-361-132:678). Bethesda, MD: National Heart, Lung and Blood Institute, Lipid Research Clinics Program. Bethesda, MD: National Heart, Lung and Blood Institute, Lipid Research Clinics Program ;
28. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006 ; 26: 847-870 (Pubitemid 44716510)
29. Otvos JD, Jeyarajah EJ, Bennett DW, et al. Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem. 1992 ; 38: 1632-1638
30. Parish S, Offer A, Clarke R, et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation. 2012 ; 125: 2469-2478
31. Chan SY, Mancini GB, Ignaszewski A, et al. Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study. BMC Clin Pharmacol. 2008 ; 8: 10
32. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol. 2001 ; 88: 270-274 (Pubitemid 32721954)